- Human pathology

Home > Technical section > Immunochemistry > IHC techniques > PD-L1 study

PD-L1 study

Monday 31 October 2016

PD-L1 IHC; PD-L1 immunochemistry


- VENTANA PD-L1 assay (SP142 assay)

- non-small cell lung cancer (NSCLC)

  • Predictive PD-L1 immunohistochemistry for non-small cell lung cancer


- Ventana SP142
- Ventana SP263
- Cell signaling E1L3N
- Dako 22C3 PharmDx
- Dako 28-8 PharmDx



Open references

- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. Sun WY, Lee YK, Koo JS. J Transl Med. 2016 Jun 10;14(1):173. doi : 10.1186/s12967-016-0925-6 PMID: 27286842 (Free)

- Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ. Oncotarget. 2015 Aug 14;6(23):19819-25. PMID: 26110571 Free